FDA Clearance Tracker · P160041
COBAS CMV
Last checked: Nov 19, 2026Latest source record: Jun 1, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jun 1, 2017
Approved (reclassified)
Time to decision
253 days
Received Sep 21, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P160041
- Device name
- COBAS CMV
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Sep 21, 2016
- Decided
- Jun 1, 2017
- Decision
- Approved (reclassified)
- Supplements
- 46 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3180
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the cobas CMV test - This device is indicated for:cobas® CMV is an in vitro nucleic acid amplification test for the quantitation of cytomegalovirus (CMV) DNA in human EDTA plasma. cobas® CMV is intended for use as an aid in the management of CMV in solid organ transplant patients and in hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from cobas® CMV must be interpreted within the context of all relevant clinical and laboratory findings. cobas® CMV is not intended for use as a screening test for blood or blood products.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
K260047 · Decided Aug 28, 2026 · 233 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
- cobas® BV/CV510(k)
K260021 · Decided Jul 16, 2026 · 192 days after receipt
Device type: Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (PQA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.